Latest news with #23andMeHoldingCo
Yahoo
22-05-2025
- Business
- Yahoo
23andMe Holding Co. (OTC:MEHCQ) Was Worth A Lot More Than People Thought, Says Jim Cramer
We recently published a list of Jim Cramer Reveals 'Quiet' Stock That Goes Up In This List Of 12 Stocks. In this article, we are going to take a look at where 23andMe Holding Co. (OTC:MEHCQ) stands against other stocks that Jim Cramer recently discussed. In a recent appearance on CNBC's Squawk on the Street, Jim Cramer commented on the recent downgrade of US credit. In a surprising development that led markets to end flat during the day, ratings agency Moody's downgraded America's perfect credit rating from the highest rating of AAA to AA+. Mentioning the development, Cramer said: "No we gotta go back to when there was a surprise. Of course when we saw S&P downgrade our. . .debt Triple A to AA+. And that was, you know we got hit pretty badly, down 6.6% in August 5th of 2011. But then we had, we had Fitch downgrade us. And that was not that bad. That was a down 1.38, when. . .And David, what's happening, that didn't happen then, was that is an alternative, the money keeps going to these European stocks. And it's rather amazing because when you look at dollar denominated, you. . .Germany and Spain up 30%!" The CNBC host also linked the lack of faith in US debt with younger generations relying on Bitcoin. He outlined: "Well, I think that Bitcoin is where, I was doing a bottle signing for my wife. . . .younger people, they don't wanna talk about stocks. They just talk about how, what a mess this debt is. So we're buying crypto. And one of them said really interesting, which was like, the President is no longer as focused on the market. President's focused on Bitcoin. Now, I think that there have been a series of articles about the President and Bitcoin. Not that complementary. But, it does point out to the fact that he sees more than. . ." To make our list of the stocks that Jim Cramer talked about, we listed down the stocks he mentioned during CNBC's Squawk on the Street aired on May 19th. For these stocks, we also mentioned the number of hedge fund investors. Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter's strategy selects 14 small-cap and large-cap stocks every quarter and has returned 373.4% since May 2014, beating its benchmark by 218 percentage points (). Number of Hedge Fund Holders In Q4 2024: N/A 23andMe Holding Co. (OTC:MEHCQ) is a healthcare company that is known for selling DNA and genetic analysis kits. It's faced a lot of turmoil which led the shares to be de-listed and to trade over-the-counter. However, 23andMe Holding Co. (OTC:MEHCQ)'s pink sheet stock soared by 261% in May after Regeneron announced that it would acquire the firm. Here is what Cramer said about the development: "One of the things that Jensen's [Jensen Huang NVIDIA CEO] been talking about . . is you need AI tools to be able to look at if you can at the correlations between genetics and disease and health for a large number of people. So what did Regeneron do today? It bought 23andMe for 256 million dollars in order to be able to get those correlations. I think it's a very smart deal, you may think that they overpaid, but to have AI and that? You may be able to find specific patterns. And that's what, uh, smart people are doing with AI. So I think that Leonard Schleifer's gonna do that. Overall, MEHCQ ranks 12th on our list of stocks that Jim Cramer recently discussed. While we acknowledge the potential of MEHCQ as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. There is an AI stock that went up since the beginning of 2025, while popular AI stocks lost around 25%. If you are looking for an AI stock that is more promising than MEHCQ but that trades at less than 5 times its earnings, check out our report about this cheapest AI stock. READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires. Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
28-03-2025
- Business
- Yahoo
23andMe's Bankruptcy Sparks Privacy Concerns Over Genetic Database Of 15 Million Customers
On Sunday, human genetics and biotechnology company 23andMe Holding Co (NASDAQ:ME) voluntarily filed for Chapter 11 bankruptcy to enable a sale process to maximize its business value. The move follows the recent rejection of a non-binding acquisition offer from CEO Anne Wojcicki and her affiliates. In November, 23andMe had announced a business restructuring to streamline operations and reduce costs. Customers who have shared their DNA with the company now risk having their genetic data sold to the highest bidder due to its bankruptcy, raising concerns about privacy and legal protections. The Bloomberg report says 23andMe has proposed a May 14 auction to sell its assets. Founded in 2006, 23andMe said in court papers that the data represents "one of the world's largest crowdsourced platforms for genetic research." In a note to customers, 23andMe said that the "Chapter 11 filing does not change how we store, manage, or protect customer data." The company boasts a database of 15 million customers company added that customers will have full access to their accounts, genetic reports, and any stored data during the process. On Tuesday, New York Attorney General Letitia James issued a consumer alert to customers of 23andMe, providing instructions on how to delete their personal data and destroy any samples of genetic material held by the company. Bloomberg report, citing a court filing, outlined that bidders must state in writing that they comply with the company's privacy practices, "which do not restrict the transfer of personally identifiable information of the debtors' customers in connection with a bankruptcy, merger, acquisition, reorganization, or sale of assets." "We are watching this bankruptcy filing closely and expect to be actively engaged to ensure sensitive records are protected and 23andMe is held accountable," Connecticut Attorney General William Tong said on Monday. In 2023, 23andMe learned that a threat actor accessed several individual accounts through credential stuffing. The data breach occurred in April 2023, and the company learned about the incident in October 2023. The company settled the lawsuits with $30 million related to the breach. A law firm representing around 5,000 customers of genetic testing company 23andMe has raised objections to a proposed $30 million class action settlement, arguing the settlement is intentionally designed to undermine claimants' rights. Read Next: Maker of the $60,000 foldable home has 3 factory buildings, 600+ houses built, and big plans to solve housing — this is your last chance to become an investor for $0.80 per share. If there was a new fund backed by Jeff Bezos offering a 7-9% target yield with monthly dividends would you invest in it? Photo via Shutterstock Up Next: Transform your trading with Benzinga Edge's one-of-a-kind market trade ideas and tools. Click now to access unique insights that can set you ahead in today's competitive market. Get the latest stock analysis from Benzinga? This article 23andMe's Bankruptcy Sparks Privacy Concerns Over Genetic Database Of 15 Million Customers originally appeared on © 2025 Benzinga does not provide investment advice. All rights reserved. Sign in to access your portfolio
Bloomberg
27-03-2025
- Automotive
- Bloomberg
Stock Movers: GM, 23andMe, Gamestop
On this episode of Stock Movers: - Ford (F) is lower today following President Trump's announcement on auto tariffs. Trump signed a proclamation to implement a 25% tariff on auto imports, aiming to bring more manufacturing jobs to the US. - 23andMe Holding Co. (ME) shares jump as much as 147% intraday Thursday, a record, after a judge ruled that the genetic testing company can try to sell information about customer data amid its bankruptcy. - Gamestop (GME) shares drop as much as 12%, the biggest intraday drop since Sept. 11, after the video-game retailer announced that it intends to offer $1.3 billion aggregate principal amount convertible senior notes due in 2030. A Wedbush analyst said he expects the offering to 'fall flat.'
Associated Press
31-01-2025
- Health
- Associated Press
23andMe Launches New Genetic Report on Osteoporosis
SUNNYVALE, Calif., Jan. 31, 2025 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME), a leading human genetics company with a mission to help people access, understand, and benefit from the human genome, today released a new polygenic risk score (PRS) report* on the genetics of osteoporosis for 23andMe+ Premium members. The report informs customers if they are at a higher likelihood of developing osteoporosis based on a statistical model developed by 23andMe through its proprietary research database, along with actionable lifestyle factors that can reduce their risk. Osteoporosis is a condition in which bone density becomes too low, which makes bones more fragile and prone to breaks (fractures). It's estimated that 12.3 million Americans have osteoporosis, and an additional 40+ million have osteopenia (a less severe form of low bone density). Osteoporosis becomes more common with age, and women are more likely to develop the condition than men. Other risk factors include having a family history of the condition, having a small body frame, taking certain medications (such as corticosteroids), and having certain other health conditions. Often called a 'silent' disease, osteoporosis usually has no symptoms until people break a bone — most commonly in the spine, hip, or wrist and often as a result of minor falls or normal activities. If diagnosed early, osteoporosis is highly actionable. There are medications that can help slow bone loss, and strategies that can help prevent falls. Importantly, healthy lifestyle habits such as exercise, diet and avoiding smoking and heavy alcohol consumption can help lower one's risk of developing the condition. Despite its actionability and health impacts, osteoporosis is often underdiagnosed and undertreated. According to the International Osteoporosis Foundation, about half of women and up to a quarter of men in the U.S. will break a bone due to low bone density, but ~80% of these individuals are never tested or treated for osteoporosis. 'Predominantly diagnosed in women, there are around 2 million new osteoporosis-related fractures in the U.S. each year, which is more than the number of new cases of heart attacks, breast cancer, and prostate cancer combined,' said Dr. Noura Abul-Husn, MD, PhD, Vice President of Genomic Health at 23andMe. 'We're proud to continue our commitment to developing genetic reports that impact women's health, adding osteoporosis to our existing slate of offerings that include breast cancer, gestational diabetes, polycystic ovary syndrome (PCOS), uterine fibroids, among others.' 23andMe's Osteoporosis PRS report* is based on a statistical model developed by 23andMe through its proprietary research database. The report takes into account an individual's genetic results at many genetic markers, along with their genetic ancestry and birth sex to estimate the likelihood of developing osteoporosis. According to published data, it's estimated that genetics explains ~60-80% of the variability in bone density. The Osteoporosis PRS report was developed by 23andMe scientists and clinical experts using 23andMe's database of genetic and health information contributed by consented research participants. A published white paper provides full details on the science and methodology behind 23andMe's PRS technology. While 23andMe's new report provides an estimate of one's likelihood of developing osteoporosis, it does not account for every possible genetic variant that could impact a person's likelihood of developing the condition, nor does it account for non-genetic factors. To learn more about the new Osteoporosis PRS report and how to become a 23andMe+ Premium member, visit About 23andMe 23andMe is a genetics-led consumer healthcare and research company empowering a healthier future. For more information, please visit Forward-Looking Statements This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including. All statements, other than statements of historical fact, included or incorporated in this press release are forward-looking statements. The words 'believes,' 'anticipates,' 'estimates,' 'plans,' 'expects,' 'intends,' 'may,' 'could,' 'should,' 'potential,' 'likely,' 'projects,' 'predicts,' 'continue,' 'will,' 'schedule,' and 'would' or, in each case, their negative or other variations or comparable terminology, are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These forward-looking statements are predictions based on 23andMe's current expectations and projections about future events and various assumptions. 23andMe cannot guarantee that it will actually achieve the plans, intentions, or expectations disclosed in its forward-looking statements and you should not place undue reliance on 23andMe's forward-looking statements. These forward-looking statements involve a number of risks, uncertainties (many of which are beyond the control of 23andMe), or other assumptions that may cause actual results or performance to differ materially from those expressed or implied by these forward-looking statements. The forward-looking statements contained herein are also subject generally to other risks and uncertainties that are described from time to time in the Company's filings with the Securities and Exchange Commission, including under Item 1A, 'Risk Factors' in the Company's most recent Annual Report on Form 10-K, as filed with the Securities and Exchange Commission, and as revised and updated by our Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. The statements made herein are made as of the date of this press release and, except as may be required by law, 23andMe undertakes no obligation to update them, whether as a result of new information, developments, or otherwise. *The 23andMe PRS reports are based on genetic models that include data from 23andMe consented research participants and incorporate thousands of genetic variants to describe if a person has a certain likelihood of developing a condition, but do not describe a person's overall likelihood. The PRS reports do not account for lifestyle or family history and have not been reviewed by the US Food and Drug Administration. The PRS reports are not intended to tell you anything about your current state of health, or to be used to make medical decisions or determine any treatment.
